Parion Sciences Incorporated Study Number PS-G202: A Phase 2a, 2-part, Randomized, Double-blind, Placebo-controlled, Incomplete Block Crossover Study to Evaluate the Safety and Efficacy of VX-371 Solution for Inhalation With and Without Oral Ivacaftor in Subjects With Primary Ciliary Dyskinesia Save

Date Added
January 25th, 2017
PRO Number
Pro00056853
Researcher
David "trey" Brown iii
Keywords
Drug Studies, Lung, Pulmonary
Summary

The Parion Sciences CLEAN-PCD study is a phase 2a, 2-part, randomized, double-blind, placebo-controlled study that will evaluate the safety and efficacy of VX-371 solution with and without oral ivacaftor in patients with primary ciliary dyskinesia (PCD). Male and female patients 12 years of age or older with a confirmed diagnosis of PCD may be eligible to participate in this study.

Study Site:
Palmetto Health/USC Department of Pediatrics
Division of Pediatric Pulmonology
9 Richland Medical Park
Columbia, SC 29203

Study Site Principal Investigator Contact Information:
David E. "Trey" Brown, MD at 803-434-7950

Institution
Palmetto
Recruitment Contact
David "Trey" Brown III
803-434-7950
ClinicalTrialSurvey@PalmettoHealth.org

Change_preferences

-- OR --

Create_login